Inventiva (NASDAQ:IVA) Trading Up 3.2% - Here's Why

Shares of Inventiva S.A. (NASDAQ:IVA - Get Free Report) shot up 3.2% during mid-day trading on Friday . The company traded as high as $3.90 and last traded at $3.89. 5,289 shares were traded during trading, a decline of 92% from the average session volume of 62,748 shares. The stock had previously closed at $3.77.

Analyst Ratings Changes

Several equities analysts have commented on IVA shares. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 price objective on shares of Inventiva in a research report on Friday, March 28th. Guggenheim decreased their price objective on shares of Inventiva from $12.00 to $9.00 and set a "buy" rating for the company in a report on Friday, April 4th. Finally, TD Cowen began coverage on shares of Inventiva in a research note on Friday, February 21st. They issued a "buy" rating and a $10.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.40.

Inventiva Trading Down 1.6 %

The firm has a 50-day simple moving average of $3.14 and a 200-day simple moving average of $2.71.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.